A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity againstShiga-like toxins and EHEC-hemolysin ofEscherichia coli O157:H7

[1]  M. Bitzan,et al.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls , 1993, Infection.

[2]  S. Ashkenazi,et al.  Effect of subinhibitory concentrations of antibiotics on extracellular shiga-like toxin I , 2005, Infection.

[3]  R. Welch,et al.  Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7 , 1996, Infection and immunity.

[4]  D. Swerdlow,et al.  Escherichia coli O157:H7 and the hemolytic-uremic syndrome. , 1995, The New England journal of medicine.

[5]  G. Armstrong,et al.  A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. , 1995, The Journal of infectious diseases.

[6]  L. Beutin,et al.  Molecular analysis of the plasmid-encoded hemolysin of Escherichia coli O157:H7 strain EDL 933 , 1995, Infection and immunity.

[7]  L. Wieler,et al.  Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle. , 1995, Veterinary microbiology.

[8]  P. Tarr.  Escherichia coli 0157:H7: Clinical, Diagnostic, and Epidemiological Aspects of Human Infection , 1995 .

[9]  C. Siddons,et al.  A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from bovine faeces. , 1994, Journal of medical microbiology.

[10]  F. Gunzer,et al.  Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology , 1993, Journal of clinical microbiology.

[11]  H. König,et al.  The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: Results of a Central European, multicentre study , 1993, Epidemiology and Infection.

[12]  H. Karch,et al.  Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples , 1993, Infection and immunity.

[13]  Infection with Escherichia coli O 157. , 1993, Communicable disease report. CDR weekly.

[14]  V. Jay,et al.  Experimental verocytotoxemia in rabbits , 1992, Infection and immunity.

[15]  G. Delage,et al.  Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. , 1992, The Journal of pediatrics.

[16]  L. Wieler,et al.  Characterization of Shiga-like toxin producing Escherichia coli (SLTEC) isolated from calves with and without diarrhoea. , 1992, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[17]  G. Armstrong,et al.  Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. , 1991, The Journal of infectious diseases.

[18]  L. Jorde,et al.  Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. , 1991, The Journal of pediatrics.

[19]  C. Gyles,et al.  Reproduction of Edema Disease of Swine with Purified Shiga-like Toxin-II Variant , 1991, Veterinary pathology.

[20]  G. Reuter,et al.  Detection and characterization of fecal verotoxin-producing Escherichia coli from healthy cattle , 1990, Journal of clinical microbiology.

[21]  S. Tzipori,et al.  Treatment with bovine hyperimmune colostrum of cryptosporidial diarrhea in AIDS patients. , 1990, AIDS.

[22]  J. Wells,et al.  Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. , 1990, The Journal of pediatrics.

[23]  J. Anderson,et al.  Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. , 1990, The Journal of pediatrics.

[24]  Z. Estrov,et al.  Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease. , 1990, International immunology.

[25]  R. Lissner,et al.  Antibodies from colostrum in oral immunotherapy. , 1990, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[26]  S. Ostroff,et al.  Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. , 1989, The Journal of infectious diseases.

[27]  J. Brown,et al.  Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1 , 1989, The Journal of cell biology.

[28]  M. Levine,et al.  Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. , 1988, The New England journal of medicine.

[29]  B. Rowe,et al.  Vero cytotoxin-producing strains of Escherichia coli from children with haemolytic uraemic syndrome and their detection by specific DNA probes. , 1988, Journal of medical microbiology.

[30]  J. Carlson,et al.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. , 1987, The New England journal of medicine.

[31]  P. Bachmann,et al.  Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis , 1987, Journal of clinical microbiology.

[32]  J. Dalrymple,et al.  Quantitative microtiter cytotoxicity assay for Shigella toxin , 1980, Journal of clinical microbiology.